- In December 2024, Ono Pharmaceutical Co., Ltd. has partnered with Congruence Therapeutics to develop novel small molecule correctors targeting multiple oncology proteins using Congruence’s Revenir platform. This collaboration will help Ono expand its oncology pipeline and accelerate the discovery of innovative treatments
- In October 2024, Sun Pharmaceutical Industries has secured a global licensing agreement with Philogen for exclusive commercialization rights to Fibromun, an innovative anti-cancer immunotherapy. This partnership will enhance Sun Pharma’s oncology portfolio and provide access to promising therapies for soft tissue sarcoma and glioblastoma treatment
